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ABSTRACT
Background Phenotypic overlap among the inherited
bone marrow failure syndromes (IBMFSs) frequently
limits the ability to establish a diagnosis based solely on
clinical features. >70 IBMFS genes have been identiﬁed,
which often renders genetic testing prolonged and
costly. Since correct diagnosis, treatment and cancer
surveillance often depend on identifying the mutated
gene, strategies that enable timely genotyping are
essential.
Methods To overcome these challenges, we developed
a next-generation sequencing assay to analyse a panel
of 72 known IBMFS genes. Cases fulﬁlling the clinical
diagnostic criteria of an IBMFS but without identiﬁed
causal genotypes were included.
Results The assay was validated by detecting 52
variants previously found by Sanger sequencing. A total
of 158 patients with unknown mutations were studied.
Of 75 patients with known IBMFS categories (eg,
Fanconi anaemia), 59% had causal mutations. Among
83 patients with unclassiﬁed IBMFSs, we found causal
mutations and established the diagnosis in 18% of the
patients. The assay detected mutant genes that had not
previously been reported to be associated with the
patient phenotypes. In other cases, the assay led to
amendments of diagnoses. In 20% of genotype cases,
the results indicated a cancer surveillance programme.
Conclusions The novel assay is efﬁcient, accurate and
has a major impact on patient care.

INTRODUCTION

To cite: Ghemlas I, Li H,
Zlateska B, et al. J Med
Genet 2015;52:575–584.

Inherited bone marrow failure syndromes (IBMFSs)
are multisystem disorders with underproductive
bone marrow and single-lineage or multilineage
cytopenia.1 Many of the disorders carry a risk of
cancer. The term IBMFSs is reserved for disorders
that are caused by germline mutations, either inherited or arising de novo with the patient.2 3 Based
on transmission patterns (eg, autosomal dominant
(AD), autosomal recessive (AR) or X-linked), segregation of alleles within families and molecular

analysis of IBMFS genes, all known IBMFSs appear
to be monogenic.4–6
The wide range of physical anomalies associated
with the IBMFSs help establish a speciﬁc diagnosis.
However, the substantial phenotypic overlap
among the disorders frequently limits the ability to
establish a diagnosis based solely on clinical manifestations. Furthermore, physical malformations
may be absent or appear later in life.7 Identifying
the speciﬁc mutated gene is essential. It helps establish a diagnosis, predict disease course (eg, cancer
risk), direct genetic counselling and treatment and
select healthy sibling donors for haematopoietic
stem cell transplantation (HSCT). Since >70
IBMFS genes have been identiﬁed, timely and costeffective strategies for genetic testing are necessary
to provide proper care.
Sanger sequencing often poses signiﬁcant limitations during the diagnostic evaluation of patients
who have or suspected to have IBMFSs. First, there
are >25 deﬁned IBMFSs with substantial clinical
overlap among as well as between IBMFSs and
acquired marrow failure syndromes. Second, individual diseases (eg, Fanconi anaemia (FA), dyskeratosis congenita (DC) and Diamond–Blackfan
anaemia (DBA)) can be caused by mutations in
multiple genes. Since Sanger sequencing of multiple
IBMFS genes is costly and lengthy,8 it is not feasible
in the setting of acute illnesses (eg, presentation
with severe aplastic anaemia (SAA)) before urgent
treatment decisions are made.
Next-generation sequencing (NGS) generates
data on multiple DNA fragments in a single reaction.9 Although application of NGS gene panels
has been reported in several heterogeneous disease
groups,10–14 there are insufﬁcient data about the
clinical impact of this genetic approach on disorders with cancer risk with regard to facilitating a
diagnosis, delivery of care and counselling of
patients and other family members. There is one
published study that used an NGS gene panel to
study a variety of IBMFSs.15 In that study that
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METHODS
Patients
The Canadian Inherited Marrow Failure Registry (CIMFR) is a
multicentre study, which was approved by the Institutional
Ethics Board of all 17 participating institutions. In Canada, all
paediatric patients with IBMFSs are typically treated in one of
the CIMFR institutions. This registry is population-based as
>90% of the patients in this study are from centres that enrol
>80% of the patients at their institutions. Patients have been
prospectively enrolled since January 2001 after obtaining
written consent. Detailed information was collected at presentation, study entry and periodic follow-up.
Individuals who fulﬁlled published diagnostic criteria for an
IBMFS5 were recruited at the participating centres of the
CIMFR. In short, the eligibility criteria include evidence of
chronic bone marrow failure in addition to either family history
or physical malformations or presentation earlier than 1 year of
age or positive genetic testing. When possible, each case was
assigned a speciﬁc syndromic diagnosis by the participating
centre. Diagnoses were reviewed centrally and if necessary were
adjusted based on published diagnostic criteria of speciﬁc
IBMFSs2 5 and after discussions with the respective centre.
Cases that fulﬁlled the diagnostic criteria of an IBMFS but did
not meet the clinical, laboratory and genetic diagnostic criteria
for any known IBMFS2 5 were deﬁned unclassiﬁed IBMFSs.8
The majority of these patients had undergone extensive genetic
testing, which was negative. Patients who presented with SAA
and did not respond to immunosuppressive therapy (ie, multilineage severe cytopenia and marrow cellularity <25% at
3 months after starting therapy) were also eligible for the
CIMFR as having unclassiﬁed IBMFSs since a proportion of
such patients would be ultimately diagnosed with IBMFS.
In the present study, 158 patients with classiﬁed or unclassiﬁed IBMFS without identiﬁed causal mutations were included;
155 were enrolled in the CIMFR and 3 were enrolled in an
internal bone marrow failure study at the Hospital for Sick
Children, Toronto. Of the 158 patients, 69 had prior clinical
genetic testing, 72 were not tested and 17 had no available data
on previous testing.
576

NGS IBMFS gene panel assay
We designed an NGS assay for a comprehensive panel of 72
IBMFS genes that had been published as of January 2013 (see
online supplementary table S1). DNA was extracted from peripheral blood in most cases. For patients with MDS/acute
myeloid leukaemia (AML), skin ﬁbroblasts, marrow ﬁbroblasts
or peripheral blood T-cells were used for DNA extraction to
minimise detection of somatic changes. We used the HaloPlex
Capture Kit (Agilent Technologies, Santa Clara, California,
USA) for DNA library preparation and capture according to the
manufacturer’s instructions. Targeted fragments were ampliﬁed
while incorporating indexes and generating linear barcoded
DNA fragments, and were sequenced on the Illumina
HiSeq2500 platform. DNA libraries from 83 patients (ﬁrst
batch) and 85 patients (second batch) were pooled, labelled
with different barcodes and sequenced in one lane.

Variant analysis and ﬁltering strategy

The algorithm used to ﬁlter non-relevant variants is described in
ﬁgure 1. To minimise false positive calls, we considered variants
as true hits if they had ≥5 positive reads. For heterozygous calls,
we also required that positive reads constitute ≥20% of the
total reads for the respective nucleotides. However, to study the
ability of the assay to detect mutations, we performed Sanger
sequencing of any homozygous variants that appeared in ≥2
reads and any heterozygous variants that appeared in ≥20% of
the reads. The software programs used to study minor allele frequency (MAF), conservation and potential damage of variants
on the protein are listed in table 1.
Variants were deﬁned as ‘causal’ if they had been reported as
disease-causing in public databases (table 1). Novel variants
were considered ‘most likely causal mutations’ if (1) they
appeared in allelic dosage that was consistent with the known
inheritance mode of the disease, (2) the MAF was <0.001,
(3) evolutionary conserved amino acid/s are affected and (4) the
variant was considered damaging by at least two of the following prediction software programs: PolyPhen2, SIFT/SIFT-Indel,
Provean, MutationTaster and Human Splicing Finder. In this
paper, we referred to both previously published mutations and
novel mutations as ‘causal mutations’.
Previously reported variants were considered ‘not causal’ if
they had been published to be polymorphic. Novel variants that
did not fulﬁl the criteria in the previous paragraph were deemed
‘most likely not causal’. Variants that fulﬁlled most but not all
the above criteria remained of unknown signiﬁcance.

Sanger sequencing
Targeted sequences were analysed after PCR ampliﬁcation by
bi-directional sequencing as previously described.16

Statistical analysis and calculation of test sensitivity
and precision
Calculation of test sensitivity and precision was performed as
previously described.17
Sanger sequencing was considered as the reference standard
method. Assay sensitivity was determined as ∑ true positive/∑
condition position, where ‘true positive’ was considered when a
mutation was observed by both NGS and Sanger sequencing
and ‘condition positive’ was considered in any case where a
mutation was observed by Sanger sequencing. Assay precision
was determined as ∑ true positive/∑ test outcome positive,
where ‘test outcome positive’ was considered as any case with
an identiﬁed causal mutation by NGS.
Ghemlas I, et al. J Med Genet 2015;52:575–584. doi:10.1136/jmedgenet-2015-103270
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included a mixed population of paediatric and adult patients
with bone marrow failure (including IBMFSs) and myelodysplastic syndromes (MDSs), the mutation detection rate was only
11%. We hypothesise that an NGS gene panel, which includes
all known genes for single and multilineage cytopenias and uses
the HaloPlex technology, could form the basis of a comprehensive testing strategy for IBMFSs in order to provide accurate
and clinically relevant molecular diagnoses in a timely fashion
and at a signiﬁcantly reduced cost.
We developed an NGS assay to sequence a panel of 72
known IBMFS genes related to disorders with pancytopenia
(eg, FA), disorders with predominantly anaemia (eg, DBA), disorders with predominantly neutropenia (eg, Kostmann/severe
congenital neutropenia (K/SCN)), disorders with predominately thrombocytopenia (eg, familial thrombocytopenia (FT))
and inherited MDS (eg, Emberger syndrome). We applied the
assay to a large population of 158 patients with IBMFSs. We
ﬁrst assessed the ability of the assay to identify causal mutations in patients that had been diagnosed with a speciﬁc
IBMFS (eg, FA, DBA, K/SCN and FT), but whose genotype
had not been identiﬁed. We then tested the ability of the assay
to identify genotypes and establish a diagnosis in patients with
unclassiﬁed IBMFSs.

Diagnostics

Table 1 Software that were used in this study to evaluate conservation, minor allele frequency and potential damage of variants on splicing
and protein structure and function

Conservation
Allele frequency

Predict potential damage of
amino acid substitution on
protein structure and function

Predict potential damage on
splicing
Reported disease-causing
mutations

Software

Source

1.
2.
1.
2.
3.

http://mutationassessor.org
http://evs.gs.washington.edu/EVS
http://evs.gs.washington.edu/EVS
http://browser.1000genomes.org/index.html
http://useast.ensembl.org/Homo_sapiens/
UserData/UploadVariations?db=core

MutationAssessor
Exome Variant Server database
Exome Variant Server
1000 Genomes
Variant Effect Predictor at the
Ensembl genome browser

1. Polymorphism Phenotyping 2
(PolyPhen2)
2. Sorting Intolerant From Tolerant
(SIFT)
3. Sorting Intolerant From Tolerant
(SIFT)—Indel
4. Protein Variation Effect Analyzer
(Provean)
5. MutationTaster
1. Human Splicing Finder 3.0
2. MutationTaster
1. SNP effect 4.0
2. The National Center for
Biotechnology Information’s
ClinVar database
3. the Leiden Open Variation
Database (LOVD)
4. Fanconi Anemia Mutation database
5. The Telomerase Database

Comments

Known polymorphism and common variants were
excluded. We used a minor allele frequency (MAF)
cut-off of 0.2% for variants in genes with AD and
XL disease inheritance, and 0.5% for variants in
genes with AR inheritance

http://genetics.bwh.harvard.edu/pph2
http://sift.jcvi.org
http://sift.bii.a-star.edu.sg/www/SIFT_
indels2.html
http://provean.jcvi.org
http://www.mutationtaster.org

http://www.umd.be/HSF
http://www.mutationtaster.org
http://snpeffect.switchlab.org
http://www.ncbi.nlm.nih.gov/clinvar
http://databases.lovd.nl/shared/genes
http://www.rockefeller.edu/fanconi/genes
http://telomerase.asu.edu/diseases.html
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Figure 1 An algorithm summarising analysis and ﬁltering processes. FA, Fanconi anaemia; LOVD, Leiden Open Variation Database; NCBI, National
Center for Biotechnology Information; PolyPhen, polymorphism phenotyping; SIFT, sorting intolerant from tolerant.
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The assay covered 456 351 bp. The average gene coverage was
99.12% (see online supplementary table S1). The average read
depth was 680×. Also, 91.2% of targeted regions were covered
with >100×. Among the 158 patients without known causal
mutations, we identiﬁed 66 393 variants. After ﬁltering (ﬁgure 1),
77 nucleotide-level variants (mutant alleles) in 59 patients were
deemed causal (tables 2 and 3; see online supplementary tables S3

Efﬁciency of variant detection
We evaluated the ability of the assay to detect 53 variants that
were found by clinical testing prior to the present study; 40 were

Table 2 Genotyping patients with classified IBMFSs and unknown genes
Clinical diagnosis

Number
tested

Number
genotyped

Mutated genes

DBA

23

16

RPS26 (het)

5

RPL11 (het)
RPS24 (het)

3
2

RPS19 (het)

3

RPL35A (het)
RPS7 (het)
SBDS (combined)

1
1
1

FANCA (hom or combined)

4

FANCA/BRIP1 (hom)
FANCE (hom)
FANCQ/ERCC4 (hom)
TINF2 (het)
ELANE (het)
HAX1 (hom)
ELANE (het)

2
1
1
1
3
1
3
1
1
2
1

FA

12

9

Number of cases with
mutations in this gene

SCN

10

4

CN

7

3

FT

4

4

DC

5

2

MYH9 (het)
ANKRD26 (het)
TERT (het)
RTEL1 (combined)

TAR

2

2

TERC (combined)
RBM8A*

1
2

CDA
SDS†

2
5

2
1

CDAN1 (combined)
SBDS (combined)

2
1

2
1
1
1
75

1
0
0
0
44

SLC25A38 (hom)

1

CSA
Radioulnar dysostosis
Reticular dysgenesis
CAMT
Total

44

Type of mutations
in this gene

Number of alleles with
this type of mutation

Indel/frameshift
Start code lost
Splicing
Indel/frameshift
Start code lost
Splicing
Splicing
Missense
Nonsense
Indel/inframe
Missense
Missense
Splicing
Missense
Indel/frameshift
Nonsense
Splicing
Nonsense
Missense
Missense
Missense
Missense
Nonsense
Missense
Indel/frameshift
Missense
Indel/frameshift
Splicing
Missense
Indel/frameshift
ncRNA
50 -UTR
Large deletion*
Missense
Indel/frameshift
Splicing
Missense

2
2
1
3
1
1
1
1
1
1
1
1
1
1
4
2
1
4
2
2
1
3
2
2
1
1
1
2
1
1
2
2
2
4
1
1
2

62‡

*Focused analysis of the NGS data at the RBM8A gene locus using the SureCall CNV algorithm identified a large deletion on the allele without the mutation (see online supplementary
figures 42 and 43). This confirmed a compound heterozygosity state, which is the commonest genotype combination in this disease.
†Four of the patients with SDS had previous SBDS testing by Sanger sequencing in a clinical lab, which was negative. No mutations in other IBMFS genes were identified in these
patients. A fifth patient had no prior testing for the SBDS gene; this patient was identified to have two SBDS mutations by the panel.
‡The total number of 62 mutant alleles includes two large deletions that were detected by focused analysis of the NGS data at the RBM8A gene using the SureCall CNV algorithm.
AD, autosomal dominant; AR, autosomal recessive; CAMT, congenital amegakaryocytic thrombocytopenia; CDA, congenital dyserythropoietic anaemia; CSA, congenital sideroblastic
anaemia; CN, cyclic neutropenia; DBA, Diamond–Blackfan anaemia; DC, dyskeratosis congenita; FA, Fanconi anaemia; FT, familial thrombocytopenia; IBMFSs, inherited bone marrow
failure syndromes; ncRNA, non-coding RNA; NGS, next-generation sequencing; SCN, severe congenital neutropenia; SDS, Shwachman–Diamond syndrome; TAR, thrombocytopenia with
absent radii.
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and S4). The majority of the mutations (44) have previously been
reported; 33 were novel (see online supplementary table S5). Of
the novel mutations, 15 were splicing mutations or indels, and 18
were missense mutations. Three of the novel mutations recurred in
more than one patient.

RESULTS
Frequencies of variants and causal mutations

Diagnostics

Clinical phenotype
Unclassified—IBMFS with
predominantly neutropenia

Unclassified—IBMFS with
bilineage or trilineage cytopenia
Unclassified—IBMFS with
bilineage or trilineage cytopenia

SAA; no response to
immunosuppressive therapy

Total

Number
tested
14

Number
genotyped
3

Genes mutated

Number of patients
with mutations
in this gene

Mutation type

Number
of alleles

Diagnosis based
on this study

GATA2 (het)

1

Missense

1

Familial MDS

WAS (hemi)
G6PC3 (hom)

1
1

Missense
Indel/frameshift

1
2

SCN
SCN

6

0

53

9

TERT (het)

3

Missense

3

DC

3

TERC (het)
TINF2 (het)
CXCR4 (het)
RPL5 (het)
MYH9 (het)
WAS (hemi)
RTEL1 (comb)

1
1
1
1
1
1
1

ncRNA
Missense
Missense
Indel/frameshift
Missense
Indel/inframe
Missense

1
1
1
1
1
1
2

DC
DC
WHIM syndrome
DBA
MYH9- related disorder
WAS
DC

TERT (Het)
MASTL (het)

1
1
15

10

83

15

Missense
Splicing

1
1
17

DC
MASTL-associated disorder

AD, autosomal dominant; AR, autosomal recessive; DBA, Diamond–Blackfan anaemia; DC, dyskeratosis congenita; eADA, adenosine deaminase; IBMFSs, inherited bone marrow failure
syndromes; IgG, immunoglobulin G; IST, immunosuppressive therapy; MDS, myelodysplastic syndrome; SAA, severe aplastic anaemia; SCN, severe congenital neutropenia; TL, telomere
length; WAS, Wiskott–Aldrich syndrome; WHIM, Warts–Hypogamaglobulinemia–Infection–Myelokathexis.

polymorphisms in 21 of the 158 subjects in this study, and 13
were causal mutations in 10 other patients on the registry that
had been genotyped (see online supplementary table S2). All
variants were detected by the NGS assay, except for one
polymorphic variant that was not covered; yielding a sensitivity
of 98%.
Next, we determined the ability of the assay to detect mutations with sizable number of reads, which we deﬁned as homozygous mutations of ≥5 reads and heterozygous mutations that
appear in ≥5 reads and constitute ≥20% of the total reads. All
76 identiﬁed such causal mutations were validated by Sanger
sequencing, giving a precision of 100% (see online supplementary ﬁgure S1–S58). Next, we studied the ability of the NGS
assay to detect mutation calls with <5 reads. Among three such
calls, two were found true by Sanger sequencing (see online supplementary ﬁgures S10 and S22). This suggests that calls with
few reads may still be true and require validation.
We encountered several cases where the NGS assay outperformed Sanger sequencing in assessing complex genotypes. For
example, the assay enabled determination whether two mutations in RTEL1 were on the same allele (ﬁgure 2A), and
whether a mutation in SBDS is true and not a contaminating
pseudogene sequence (ﬁgure 2B).

Genotyping patients with classiﬁed IBMFSs
Of the 75 IBMFS patients with clinically classiﬁed IBMFSs
(table 2), we identiﬁed 60 nucleotide-level causal mutations (9
of them were homozygous) in 44 patients (59%) by the NGS
assay (see online supplementary table S3). Among patients who
had not had previous genetic testing, 66% were genotyped.
DBA was the most common IBMFS in the Canadian registry, followed by FA; among these disorders, 70% and 75% were found
to have causal mutations by the NGS assay, respectively.
The NGS assay helped establish a precise diagnosis and discriminate between disorders with similar initial phenotypes but
Ghemlas I, et al. J Med Genet 2015;52:575–584. doi:10.1136/jmedgenet-2015-103270

different natural histories. For example, one of two patients
with FT (see online supplementary table S3, patients 38 and 39)
had a mutation in MYH9, leading to a speciﬁc diagnosis of
MYH9-associated FT, while the other was classiﬁed as having
ANKRD26-associated FT, based on having a frameshift mutation
in the ANKRD26 gene. This frameshift causes loss of the last 50
amino acids of the protein, a region that is critical for the
binding of ANKRD26 to its partner, TRIO, that shares cellular
functions with ANKRD26.18 Importantly, in contrast to
MYH9-associated FT, ANKRD26-associated FT is associated
with an increased risk of haematological malignancies19 and
indicates cancer surveillance.20
The analysis of two cases of thrombocytopenia with absent
radii (TAR) syndrome exempliﬁes how compound heterozygosity that includes both one allelic deletion and a nucleotide-level
mutation can be detected by NGS. Such a compound heterozygosity in RBM8A is the commonest cause of TAR syndrome.6 21
The NGS data indicated a previously reported mutation in
50 -UTR area of RBM8A in both patients (ﬁgure 3A, see online
supplementary table S3, patients 43 and 44). To determine
whether the patients have homozygous mutations or compound
heterozygosity with a submicroscopic monoallelic deletion, we
used the SureCall CNV detection algorithm and our NGS data.
Comparison of read numbers along RBM8A in these patients
with ﬁve other subjects (ﬁgure 3B) suggested one allelic deletion
in both patients. Copy number analysis in one of these cases by
Affymetrix SNP6.0 array validated a submicroscopic deletion
(ﬁgure 3C).

Amendment of diagnoses
The diagnosis of four clinically classiﬁed patients (9%) was
amended after the results of the NGS gene panel assay became
available. The ﬁrst example is of a mother and son who were
clinically diagnosed with non-syndromic FT (see online supplementary table S3, patients 40 and 41). Both were found to be
579
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Table 3 Genotyping of patients with unclassified inherited bone marrow failure syndromes

Diagnostics

heterozygous for a TERT mutation c.2383-15T>C (ﬁgure 4A),
which was predicted to disrupt the binding site of splicing
factor SRp40 and break the adjacent splicing site (see online
supplementary table S5, patient 9). This mutation appeared in
another unrelated patient in our registry, who had aplastic
anaemia, very short telomeres in the range that is characteristic
to DC and response to androgen therapy (ﬁgure 4B, see online
supplementary table S2, patient 9). This mutation is very rare in
the general population. Based on this information, the diagnosis
was changed to DC.
The third patient was diagnosed clinically with FA based on
haematological ﬁndings noticed at the age of 12.5 months, nonhaematological features and increased chromosome fragility
with hypersensitivity to mitomycin C and diepoxybutane (see
online supplementary table S3, patient 25). Using the NGS
assay, we found a mutation in TINF2 (c.734C>A) (ﬁgure 4C),
which was previously reported in a patient with aplastic
580

anaemia. Accordingly, the diagnosis was amended to DC.
Varying degree of chromosomal instability has been reported in
DC,22–25 but not to the degree found in this patient. Telomere
length measurement was not available before the patient died.
The fourth patient was diagnosed with DBA based on severe
anaemia, reticulocytopenia and markedly reduced marrow erythrocytes (see online supplementary table S3, patient 16).
Marrow cellularity was reduced for the patient’s age (70%), and
moderate neutropenia (0.69×109/L) was registered once. The
patient failed to respond to steroids. We found two mutations in
SBDS (ﬁgure 4D): c.258+2T>C, which is the most common
SBDS mutation, and c.127G>T, which is predicted to replace
valine with leucine. Importantly, the substitution of G at the
second last nucleotide of exon 1 (c.127) is also predicted to
break the adjacent splice donor site. Sequencing of samples
from the patient’s parents showed that each parent was heterozygous for one of these mutations (ﬁgure 4E), conﬁrming the
Ghemlas I, et al. J Med Genet 2015;52:575–584. doi:10.1136/jmedgenet-2015-103270
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Figure 2 Next-generation sequencing (NGS) inherited bone marrow failure syndromes gene panel assay revealed challenging genotypes. (A) Using
BAM ﬁles to depict results of massive parallel sequencing, each of the obtained sequences of RTEL1 (see online supplementary table S4, patient 13)
could be visualised separately. Both variants are located closer than the 150 bp size of the oligonucleotides used and it is possible to determine that
they are on different alleles (and read). (B) SBDS and its pseudogene (SBDSP1) share 97% homology. Both were ampliﬁed by the designed NGS
oligonucleotide. Sequences from several patients with the c.258+2T>C variant are seen. This common SDS variant results from conversion with
SBDSP1. Based on the difference between SBDS sequences upstream to the mutation (TTTTT) and SBDSP1 (TTCTT), we can discriminate true
mutation from a contaminating SBDSP1 sequence. Patients 1 and 4 have c.258+2T>C variant together with the SBDS sequence TTTTT, therefore,
those variants are real SBDS mutations. Patients 2 and 3 have c.258+2T>C variant together with the SBDSP1 sequence, TTCTT, indicating that these
sequences are of SBDSP1 sequences and not real SBDS mutations. Patient 5 has both, c.258+2T>C variant and TTCTT, but they exist in different
fragments, indicating that both are real SBDS mutations, and that they exist in different alleles.
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biallelic nature of the maturations in the child. Sequencing of
reverse transcription PCR products using three different pairs of
primers repeatedly showed multiple cDNA products consisting
with alternative splicing by both mutations. The overall SBDS
protein was reduced to 60% of the level in normal samples
(ﬁgure 4F). Based on the above, a diagnosis of SDS was deemed
more likely than DBA.

patients 13–15). Two patients had mutations in pancytopeniaassociated genes, RTEL1 and TERT. Surprisingly, one patient
had a mutation in microtubule-associated serine/threonine kinaselike (MASTL), which would not have been normally tested in
cases of SAA, as so far it has been associated only with FT.

Identifying mutations and establishing diagnoses in patients
with unclassiﬁed IBMFSs

In 20% of genotype cases, the results indicated a cancer surveillance programme and proper family counselling. One example
is a patient with chronic severe neutropenia and marrow monosomy 7 (see online supplementary table S4, patient 1), who was
found to have a mutation in GATA2. Another example is a
patient with chronic moderate neutropenia (see online supplementary table S4, patient 2), solitary kidney and hypocellular
bone marrow, who was found to have an activating WAS
mutation.29

Eighty-three patients with unclassiﬁed IBMFSs were studied.
These patients posed major diagnostic dilemmas and frequently
underwent multiple testing over many years. We identiﬁed 17
causal mutations and established the speciﬁc IBMFS diagnosis
in 15 patients (18%) (table 3, see online supplementary
ﬁgure S59).
Three of the successfully genotyped unclassiﬁed patients with
IBMFS had predominantly neutropenia (see online supplementary table S4, patients 1–3). Two patients had mutations in
known K/SCN genes: WAS and G6PC3. However, in one case the
mutated gene, GATA2, was not known as a K/SCN gene,26–28
and biased testing for K/SCN-related genes would not have identiﬁed the causal genotype.
Nine of the successfully genotyped unclassiﬁed patients with
IBMFS had multilineage cytopenia (see online supplementary
table S4, patients 4–12). Five of these patients were ultimately
diagnosed with DC due to mutations in telomere maintenanceassociated genes (see online supplementary table S4, patients
4–8). The haematological phenotype of these patients with DC
varied from predominantly anaemia to moderate aplastic
anaemia and SAA. Interestingly, three other patients with pancytopenia were ultimately diagnosed with predominantly neutropenia syndrome (Warts–Hypogamaglobulinemia–Infection–
Myelokathexis (see online supplementary table S4, patient 9),
predominantly erythrocytopenia syndrome (DBA, see online
supplementary table S4, patient 10) or predominantly thrombocytopenia syndrome (MYH9-related FT) (see online supplementary table S4, patient 11). These three patients would not have
been genotyped if only pancytopenia-related genes had been
sequenced.
Three genotyped unclassiﬁed patients with IBMFS belonged
to a group of 10 patients who had SAA and no response to
immunosuppressive therapy (see online supplementary table S4,
Ghemlas I, et al. J Med Genet 2015;52:575–584. doi:10.1136/jmedgenet-2015-103270

Changing indications for implementation of cancer
surveillance programme

Expanding syndromes’ phenotype
Our study expanded the known phenotype of two syndromes.
Neutropenia has not been reported as a feature of
MYH9-associated FT.30 One of the patients with unclassiﬁed
IBMFSs presented with early-onset thrombocytopenia and neutropenia, which persisted at moderate level (see online supplementary table S4, patient 11). The successful genotyping
suggests that mutations in MYH9 may also cause neutropenia.
The second syndrome is MASTL-associated disorder, which thus
far has been linked only to non-syndromic FT, but the results in
our study suggest that it can also be associated with SAA.

Cost consideration
We compared the cost of NGS assay to the cost of clinical
testing for 30 patients with IBMFS enrolled at one of the
CIMFR institutions (the Hospital for Sick Children, Toronto)
between December 2010 and December 2013. Also, 21/30 had
clinical genetic testing, averaged 5.95 tests/patient and US
$4643/patient. These costs did not include expenses of DNA
extraction and shipping to designated laboratories. The cost of
NGS averaged $470/patient. This included reagents, sequencing
service, bioinformatics and salary. In case of urgent testing
without sequencing batching, the maximum price for NGS
testing would be $2605/patient. This cost did not include a
proﬁt charge in the NGS cost, while this charge was
581

J Med Genet: first published as 10.1136/jmedgenet-2015-103270 on 1 July 2015. Downloaded from http://jmg.bmj.com/ on July 4, 2022 by guest. Protected by copyright.

Figure 3 Revealing deletions in the RBM8A gene. (A) A previously described missense mutation in the RBM8A gene: c.-21G>A was detected by
the NGS data (upper panel) and validated by Sanger sequencing (lower panel). Only a mutant allele was detected, which suggests either a
homozygous mutation or a nucleotide-level mutation that is accompanied by a deletion on the other allele. (B) Copy number analysis was detected
in the RBM8A gene. Patient read numbers in the gene region obtained from the NGS data were compared with read numbers from ﬁve subjects by
the SureCall software. One copy number deletion was found as indicated by log2 of <0.6 when patient calls are compared with each of the other
controls. (C) One copy number deletion in the RBM8A gene was validated by the Affymetrix SNP6.0 array.
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incorporated in the service cost by the clinical laboratories. It is
anticipated that rapid genotyping will not only reduce cost of
genetic testing but also the cost of frequent clinic visits after
presentation and other diagnostic ancillary laboratory tests such
as skeletal survey, telomere length, adenosine deaminase levels,
chromosome fragility test and pancreatic function tests.

DISCUSSION
We evaluated the effectiveness of a new comprehensive NGS
IBMFS gene panel assay on a large cohort of patients with
IBMFSs and showed that it detects mutations with high sensitivity and precision. The test assisted in establishing a diagnosis in
difﬁcult cases and amended diagnoses that have been established
solely on clinical basis. It is rapid, cost-effective and yields highpositive hits compared with the typical diagnostic odyssey that
many of these patients with IBMFS encounter.
Our assay was effective in identifying causal mutations in 59%
of the classiﬁed cases and led to amendment of clinical diagnoses
582

in 9% of the genotyped cases. This exempliﬁes the potential pitfalls of targeting a speciﬁc diagnosis in patients with IBMFSs,
even when the clinical features are highly suggestive of that disorder. These pitfalls can be overcome only by a comprehensive
panel testing of all IBMFS genes that associated with single and/
or multilineage cytopenias, and not by panel assays that are
restricted to genes associated with one disease/phenotype.
The results of this study also underscore the advantage of
comprehensive testing in unclassiﬁed IBMFSs. We genotyped
and consequently established a diagnosis in 18% of these cases.
Our study uncovered atypical presentations of patients with speciﬁc genotypes (eg, certain MASTL mutations in SAA) that allow
expansion of clinical deﬁnitions of syndromes and reﬁnement of
their diagnostic criteria. Although the number of patients with
SAA that did not respond to immunosuppressive therapy that
tested herein was only 10, the proportion of successfully genotyped patients appears to be higher (30%) than that in previous
reports (<5%).31–33 This is the ﬁrst report of a patient with
Ghemlas I, et al. J Med Genet 2015;52:575–584. doi:10.1136/jmedgenet-2015-103270
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Figure 4 Mutations that lead to amendment of diagnosis. (A) Heterozygous mutation in TERT, c.2383-15C>T, was identiﬁed in a mother and son
who were clinically diagnosed as autosomal-dominant non-syndromic familial thrombocytopenia (see also online supplementary table S3, patient
40). Bone marrow biopsy at the age of 17 years showed cellularity of 70%. The upper panel shows the nucleotide-level sequence by the BAM
next-generation sequencing (NGS) ﬁle, which is the DNA reverse-complement counterpart. The lower panel shows the results of Sanger sequencing.
(B) Telomere length in various peripheral blood cell lineages from a with TERT mutations c.2383-15C>T in the study was measured by ﬂow
ﬂuorescent in situ hybridisation. The dots represent the patient values. The lines represent percentiles of telomere length among 391 healthy control
persons ranging from birth to 100 years of age done in Repeat Diagnostic Laboratory (Vancouver, Canada). (C) TINF2 mutation in a patient who was
clinically diagnosed with Fanconi anaemia (FA). The upper panel shows the nucleotide-level sequence as found by NGS. The lower panel shows the
results of Sanger sequencing. The patient underwent haplo-identical haematopoietic stem cell transplantation from her parent with FA-adjusted
conditioning, but did not engraft. The patient had also a novel germline RUNX1 variant in the marrow ﬁbroblast DNA that was tested (c.383T>C,
V128A), which might have contributed to her disease course. (D) SBDS mutations in a patient that was diagnosed clinically with Diamond–Blackfan
anaemia. The upper panel shows the nucleotide sequence as found by next-generation sequencing. The middle panel shows the results of Sanger
sequencing. (E) Sanger sequencing of SBDS in parents’ samples. (F) for western blotting of the SBDS protein in the patient with SBDS mutations:
c.127G>T/SBDS c.258+2T>C (P) and two controls (C1, C2) (C, control; P, patient).
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SAA who was tested and found positive for mutations in
MASTL. MASTL-associated IBMFS is AD and is characterised by
moderate thrombocytopenia. Platelets are of normal size and
function. Haemoglobin levels and neutrophils were reported to
be normal. Marrow megakaryocytes are typically reduced.34–36
Our study shows that the NGS assay can have a major impact
on clinical care. For example, the amendment of clinical diagnosis of FA to DC in one of the patients indicates a need for substantially more intensive HSCT preparatory regimen to achieve
successful engraftment. Further, patients with IBMFS with
similar presentations were found to have syndromes that carry
markedly different cancer risk. For examples, patients with isolated neutropenia were classiﬁed as having a GATA2-associated
disorder (very high risk of leukaemia, no risk of carcinomas) or
a CXCR4-associated disorder (low or potentially absence of a
risk of leukaemia, risk of mucocutaneous carcinoma). Also, four
patients with a clinical diagnosis of non-syndromic FT were
accurately categorised as having either ANKRD26-associated FT
and DC (substantial risk of MDS/AML) or MYH9-related FT
(no risk of MDS/AML).
Not all patients were genotyped by the NGS assay. This might
be due to incomplete target coverage (∼1%), exclusion of deep
intronic areas, large indels, inability of bioinformatics tools to
determine whether certain rare variant are causal and/or incomplete knowledge of all the IBMFS genes. Small indels and promoter mutations are captured by our panel design. In a
proportion of the patients with FA, one allele of an early haematopoietic stem cells/progenitor undergoes spontaneous genetic
correction and the respective developing precursors lose the
increased chromosome fragility phenotype. This results in a
mixture of healthy and FA cells and peripheral blood cell mosacism on chromosome fragility testing. In compound heterozygous cases, NGS will be able to detect the aberrant reads from
non-corrected alleles. In most cases with homozygous mutations
and mosacism, functional correction results in a sequence that is
not identical to the wild-type one and the non-corrected mutant
allele will still be identiﬁed by NGS. Genetic counselling should
always be recommended, and the above limitations should be
mentioned when results are disclosed to patients. Similar to
reports of Sanger sequencing results, novel variants may be
reported as likely positive or likely negative. Newly discovered
genes can be incorporated in the panel as they are discovered by
determining the precise coordinates of the fragments to be
sequenced and designing oligonucleotides as described in online
supplementary table S1. Hence, periodic repeat testing by
updated gene panels may result in successful genotyping. Our
assay can serve as a screening test before applying gene discovery methods such as exome sequencing.
In summary, our novel NGS IBMFS gene panel assay is a
rapid, accurate and cost-effective strategy to genetically investigate patients with IBMFSs. The correct classiﬁcation of IBMFs
by NGS facilitates the more accurate medical management of
these complex conditions. Therefore, we propose that NGS gene
panels be considered as the ﬁrst-line clinical molecular diagnostic
test when the list of potentially mutated genes includes multiple
candidates; this applies to the majority of patients with IBMFSs.
Similar strategies may also be applied to other groups of genetic
disorders with variable disease expression and presentation.

Diagnostics
9

11
12

13

14

15

16
17

18

19

20
21

22
23

584

24
25

26

27

28

29

30

31
32

33

34

35

36

Murnane JP. Telomere dysfunction and chromosome instability. Mutat Res
2012;730:28–36.
Sabatier L, Ricoul M, Pottier G, Murnane JP. The loss of a single telomere can result
in instability of multiple chromosomes in a human tumor cell line. Mol Cancer Res
2005;3:139–50.
Hsu AP, Sampaio EP, Khan J, Calvo KR, Lemieux JE, Patel SY, Frucht DM, Vinh DC,
Auth RD, Freeman AF, Olivier KN, Uzel G, Zerbe CS, Spalding C, Pittaluga S,
Raffeld M, Kuhns DB, Ding L, Paulson ML, Marciano BE, Gea-Banacloche JC,
Orange JS, Cuellar-Rodriguez J, Hickstein DD, Holland SM. Mutations in GATA2 are
associated with the autosomal dominant and sporadic monocytopenia and
mycobacterial infection (MonoMAC) syndrome. Blood 2011;118:2653–5.
Ostergaard P, Simpson MA, Connell FC, Steward CG, Brice G, Woollard WJ, Dafou
D, Kilo T, Smithson S, Lunt P, Murday VA, Hodgson S, Keenan R, Pilz DT,
Martinez-Corral I, Makinen T, Mortimer PS, Jeffery S, Trembath RC, Mansour S.
Mutations in GATA2 cause primary lymphedema associated with a predisposition to
acute myeloid leukemia (Emberger syndrome). Nat Genet 2011;43:929–31.
Hahn CN, Chong CE, Carmichael CL, Wilkins EJ, Brautigan PJ, Li XC, Babic M, Lin
M, Carmagnac A, Lee YK, Kok CH, Gagliardi L, Friend KL, Ekert PG, Butcher CM,
Brown AL, Lewis ID, To LB, Timms AE, Storek J, Moore S, Altree M, Escher R, Bardy
PG, Suthers GK, D’Andrea RJ, Horwitz MS, Scott HS. Heritable GATA2 mutations
associated with familial myelodysplastic syndrome and acute myeloid leukemia.
Nat Genet 2011;43:1012–17.
Ancliff PJ, Blundell MP, Cory GO, Calle Y, Worth A, Kempski H, Burns S, Jones GE,
Sinclair J, Kinnon C, Hann IM, Gale RE, Linch DC, Thrasher AJ. Two novel activating
mutations in the Wiskott-Aldrich syndrome protein result in congenital neutropenia.
Blood 2006;108:2182–9.
Seri M, Cusano R, Gangarossa S, Caridi G, Bordo D, Lo Nigro C, Ghiggeri GM,
Ravazzolo R, Savino M, Del Vecchio M, d’Apolito M, Iolascon A, Zelante LL,
Savoia A, Balduini CL, Noris P, Magrini U, Belletti S, Heath KE, Babcock M,
Glucksman MJ, Aliprandis E, Bizzaro N, Desnick RJ, Martignetti JA. Mutations
in MYH9 result in the May-Hegglin anomaly, and Fechtner and Sebastian
syndromes. The May-Heggllin/Fechtner Syndrome Consortium. Nat Genet
2000;26:103–5.
Du HY, Mason PJ, Bessler M, Wilson DB. TINF2 mutations in children with severe
aplastic anemia. Pediatr Blood Cancer 2009;52:687.
Pigullo S, Pavesi E, Dianzani I, Santamaria G, Svahn J, Risso M, Van Lint MT, Pillon
M, Iori AP, Longoni D, Ramenghi U, Lanciotti M, Dufour C. NOLA1 gene mutations
in acquired aplastic anemia. Pediatr Blood Cancer 2009;52:376–8.
Field JJ, Mason PJ, An P, Kasai Y, McLellan M, Jaeger S, Barnes YJ, King AA,
Bessler M, Wilson DB. Low frequency of telomerase RNA mutations among children
with aplastic anemia or myelodysplastic syndrome. J Pediatr Hematol Oncol
2006;28:450–3.
Drachman JG, Jarvik GP, Mehaffey MG. Autosomal dominant thrombocytopenia:
incomplete megakaryocyte differentiation and linkage to human chromosome 10.
Blood 2000;96:118–25.
Gandhi MJ, Cummings CL, Drachman JG. FLJ14813 missense mutation: a candidate
for autosomal dominant thrombocytopenia on human chromosome 10. Hum Hered
2003;55:66–70.
Johnson HJ, Gandhi MJ, Shaﬁzadeh E, Langer NB, Pierce EL, Paw BH, Gilligan DM,
Drachman JG. In vivo inactivation of MASTL kinase results in thrombocytopenia.
Exp Hematol 2009;37:901–8.

Ghemlas I, et al. J Med Genet 2015;52:575–584. doi:10.1136/jmedgenet-2015-103270

J Med Genet: first published as 10.1136/jmedgenet-2015-103270 on 1 July 2015. Downloaded from http://jmg.bmj.com/ on July 4, 2022 by guest. Protected by copyright.

10

Rizzo JM, Buck MJ. Key principles and clinical applications of “next-generation”
DNA sequencing. Cancer Prev Res (Phila) 2012;5:887–900.
Amstutz U, Andrey-Zurcher G, Suciu D, Jaggi R, Haberle J, Largiader CR. Sequence
capture and next-generation resequencing of multiple tagged nucleic acid samples
for mutation screening of urea cycle disorders. Clin Chem 2011;57:102–11.
Vasta V, Ng SB, Turner EH, Shendure J, Hahn SH. Next generation sequence
analysis for mitochondrial disorders. Genome Med 2009;1:100.
Meder B, Haas J, Keller A, Heid C, Just S, Borries A, Boisguerin V, ScharfenbergerSchmeer M, Stahler P, Beier M, Weichenhan D, Strom TM, Pfeufer A, Korn B, Katus
HA, Rottbauer W. Targeted next-generation sequencing for the molecular genetic
diagnostics of cardiomyopathies. Cir Cardiovasc Genet 2011;4:110–22.
DaRe JT, Vasta V, Penn J, Tran NT, Hahn SH. Targeted exome sequencing for
mitochondrial disorders reveals high genetic heterogeneity. BMC Med Genet
2013;14:118.
Berg JS, Evans JP, Leigh MW, Omran H, Bizon C, Mane K, Knowles MR, Weck KE,
Zariwala MA. Next generation massively parallel sequencing of targeted exomes to
identify genetic mutations in primary ciliary dyskinesia: implications for application
to clinical testing. Genet Med 2011;13:218–29.
Zhang MY, Keel SB, Walsh T, Lee MK, Gulsuner S, Watts AC, Pritchard CC,
Salipante SJ, Jeng MR, Hofmann I, Williams DA, Fleming MD, Abkowitz JL, King
MC, Shimamura A. Genomic analysis of bone marrow failure and myelodysplastic
syndromes reveals phenotypic and diagnostic complexity. Haematologica
2015;100:42–8.
Majeed F, Jadko S, Freedman MH, Dror Y. Mutation analysis of SBDS in pediatric
acute myeloblastic leukemia. Pediatr Blood Cancer 2005;45:920–4.
Nicoll D, Detmer W. Current medical diagnosis & treatment. In: Tierney LM Jr,
McPhee SJ, Papadekis MA, eds. Basic Principles of Diagnostic Test Use and
Interpretation, 36th edn. Stamford, CT: Appleton & Lange, 1997:1–16.
Liu XF, Bera TK, Kahue C, Escobar T, Fei Z, Raciti GA, Pastan I. ANKRD26 and its
interacting partners TRIO, GPS2, HMMR and DIPA regulate adipogenesis in 3T3-L1
cells. PLoS One 2012;7:e38130.
Noris P, Favier R, Alessi MC, Geddis AE, Kunishima S, Heller PG, Giordano P,
Niederhoffer KY, Bussel JB, Podda GM, Vianelli N, Kersseboom R, Pecci A, Gnan C,
Marconi C, Auvrignon A, Cohen W, Yu JC, Iguchi A, Miller Imahiyerobo A, Boehlen
F, Ghalloussi D, De Rocco D, Magini P, Civaschi E, Biino G, Seri M, Savoia A,
Balduini CL. ANKRD26-related thrombocytopenia and myeloid malignancies. Blood
2013;122:1987–9.
Balduini CL, Pecci A, Noris P. Diagnosis and management of inherited
thrombocytopenias. Semin Thromb Hemost 2013;39:161–71.
Klopocki E, Schulze H, Strauss G, Ott CE, Hall J, Trotier F, Fleischhauer S,
Greenhalgh L, Newbury-Ecob RA, Neumann LM, Habenicht R, Konig R, Seemanova
E, Megarbane A, Ropers HH, Ullmann R, Horn D, Mundlos S. Complex inheritance
pattern resembling autosomal recessive inheritance involving a microdeletion in
thrombocytopenia-absent radius syndrome. Am J Hum Genet 2007;80:232–40.
DeBauche DM, Pai GS, Stanley WS. Enhanced G2 chromatid radiosensitivity in
dyskeratosis congenita ﬁbroblasts. Am J Hum Genet 1990;46:350–7.
Deng Z, Glousker G, Molczan A, Fox AJ, Lamm N, Dheekollu J, Weizman OE,
Schertzer M, Wang Z, Vladimirova O, Schug J, Aker M, Londono-Vallejo A, Kaestner
KH, Lieberman PM, Tzfati Y. Inherited mutations in the helicase RTEL1 cause
telomere dysfunction and Hoyeraal-Hreidarsson syndrome. Proc Natl Acad Sci USA
2013;110:E3408–16.

